“…Committee members drew upon a wide range of information such as scientific literature, clinical anecdotes, regional trends in hospital admission and drug utilization, budget data, formularies in other jurisdictions, previous decisions, contracts with pharmaceutical companies, and stakeholder input. This finding highlights that decision-makers performing drug formulary priority-setting, akin to those operating in other policy-making contexts, utilize a "mixed economy" of evidence [19][20][21][22][23][24].…”